Clinical Trial Update: A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation [Phase 3]

View source ↗

Summary

Withdrawn: Phase III trial evaluating Lactobacillus CD2 lozenges to prevent high-dose chemotherapy-induced oral mucositis in patients undergoing myeloablative h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Mucositis

Drugs mentioned

• Lactobacillus CD2 Lozenges (Lactobacillus CD2)

Snippet

Sponsor: All India Institute of Medical Sciences | Conditions: Oral Mucositis in Patients Undergoing HSCT | Phase 3 | Status: WITHDRAWN